Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation

Hong Chang, X. Y. Qi, S. Samiee, Q. L. Yi, C. Chen, S. Trudel, J. Mikhael, D. Reece, A. K. Stewart

Research output: Contribution to journalArticle

55 Scopus citations


Genetic aberrations have emerged as major prognostic factors for patients with multiple myeloma (MM). We evaluated 126 MM patients for t(4;14) or t(11;14), 13q or p53 deletions and correlated the number of genetic aberrations with patient's clinical outcome following undergoing autologous stem cell transplantation. We demonstrate the significance of genetic-based risk classification that clearly segregate patients into low (no genetic abnormalities or only t(11;14)), intermediate (any one of the genetic abnormalities other than t(11;14)) and high-risk groups (any two or more of the genetic abnormalities other than t(11;14)). High-risk patients do not benefit from stem cell transplant and should be offered alternative therapies.

Original languageEnglish (US)
Pages (from-to)793-796
Number of pages4
JournalBone Marrow Transplantation
Issue number9
StatePublished - Nov 1 2005



  • 13q deletions
  • Autologous stem cell transplantation
  • Fluorescence in situ hybridization
  • IgH translocations
  • Multiple myeloma
  • p53 deletions

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this